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Letters
Author Response: Statin Use and Open-Angle
Glaucoma: Evidence From Observational
Studies
We read with interest the letter titled ‘‘Statin Use and Open-
Angle Glaucoma: Evidence From Observational Studies’’ from
Ng and colleagues.1 We would like to thank the authors for the
constructive scrutiny of our study design2 in relation to (1)
placement of studies in the meta-analysis, (2) the process of
appraising the quality of evidence of the included studies, and
(3) appropriateness of inclusion of studies in the systematic
review. Below we aim to address the points raised by Ng and
colleagues.
1. Placement of studies in the meta-analysis
We thank the authors for raising the discussion regarding
our assignment of ‘‘suspected glaucoma conversion to open-
angle glaucoma (OAG)’’ as ‘‘progression’’ rather than ‘‘inci-
dence.’’ In light of the definition of OAG suspect in the
American Academy of Ophthalmology Preferred Practice
Pattern Guidelines,3 we agree that there is room for discussion
around this point. We would like to thank the authors for the
amended meta-analysis, which includes ‘‘suspect to OAG’’ in
the forest plot on incidence of glaucoma and statin use > 2
years. As the authors have noted, development of ‘‘outside
normal limits’’ on Humphrey Field Analyzer hemifield measure-
ment should be classified as ‘‘incidence of OAG’’ rather than
‘‘progression’’; therefore we have added the results of De
Castro et al.4 to the forest plot on incidence of glaucoma and
statin use > 2 years (Fig. 1). For the purposes of our analysis,
controls were the ‘‘did not take statins’’ (n ¼ 39) and ‘‘aspirin
only’’ (n¼13) groups. Those who took statins were the ‘‘statins
only’’ (n¼ 12) and ‘‘statinsþ aspirin’’ (n¼ 12) groups. We also
added ‘‘suspect to OAG’’ analysis to the forest plot on incidence
of glaucoma and statin use  2 years (Fig. 2).
2. The process of appraising the quality of evidence of the
included studies
We thank the authors for the revision of the Newcastle
Ottawa Scale (NOS) scores for the cohort studies and accept
most of their interpretations. However, we have given a mark to
De Castro et al.4 for ‘‘demonstration that outcome of interest
was not present at start of study’’ because eligible participants
had ‘‘no visual field defect’’ at baseline but had hemifield
defects when they became OAG cases (Table 1). It is debatable
that De Castro et al.4 should not be given a mark for
‘‘ascertainment of exposure’’ because a documented medical
history could be interpreted as a secure record; however, we
have agreed with the authors’ conservative approach. In the
case–control study NOS scores, a study received a mark for
‘‘additional factors the studies control for’’ only if diabetes and
other ocular parameters were controlled for as suggested by the
authors for cohort studies (Table 2). The cutoff point for the
presence of bias was changed from 7 to <6 because 7
would exclude all the studies from the meta-analysis. The figure
<6 was chosen because the mean of the NOS scores of the six
studies included in the meta-analyses was 6.
3. Appropriateness of inclusion of studies in the systematic
review
We accept that the case–control study by Owen et al.10
defined cases based on diagnostic codes for glaucoma,
prescription for glaucoma medications, and ocular hyperten-
sion, and this was described in our study (Table 3 in the article).
We agree that there is a lack of information on the proportion
of cases with diagnostic code for ocular hypertension. We also
accept that ocular hypertension is not a subtype of glaucoma
and therefore there is a valid argument for the exclusion of the
study from the meta-analyses. However, we believe that
discussion of the results in the systematic review and
exploration of the implications of removing these results in
sensitivity analyses would be pragmatic given the relative lack
of studies identified.
We agree that the cross-sectional study by Khawaja et al.12
was not able to infer a causal relationship between statin use
and IOP due to its cross-sectional design. However, we disagree
that this is justification for the study to be excluded from the
systematic review. The identification of concurrent beta-
blocker therapy as the explanation for the association between
statin therapy and IOP is an important finding.
SENSITIVITY ANALYSIS
A revised sensitivity analysis was conducted following the
changes to the NOS scoring and changes to the studies that
were included in the forest plots. To address the issue of ocular
hypertension in the case mix in the case–control study by
Owen et al.,10 sensitivity analysis was performed on meta-
analyses that included the results of this study. Removal of
Owen et al.10 from the meta-analysis of glaucoma incidence in
statin exposure for 2 years resulted in no change to the
statistical significance of the result (with Owen et al.,10 odds
ratio [OR] 0.96, 95% confidence interval [CI] 0.94, 0.98;
without Owen et al.,10 OR 0.96, 95%CI 0.93, 0.98). Removal of
FIGURE 1. Forest plot of incidence of glaucoma and statin use > 2 years versus control. Marcus et al.7: Upper limit of 95%CI (0.92) is not exactly
equivalent to upper limit of 95%CI in Table 3 of original article (0.94) due to rounding in meta-analysis software.
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FIGURE 2. Forest plot of incidence of glaucoma and statin use  2 years versus controls. McGwin et al.9 (12–23 months): Upper limit of 95%CI
(1.38) is not exactly equivalent to upper limit of 95%CI in Table 3 of original article (1.39) due to rounding in meta-analysis software.
TABLE 1. Newcastle-Ottawa Scale: Cohort Studies
Domain DeCastro et al.4 2007 Iskedjian et al.5 2009 Leung et al.6 2010 Marcus et al.7 2012 Stein et al.8 2012
Selection
Representativeness of
the exposed cohort
No description of the
derivation of the
cohort (university-
based eye center)
(0)
Somewhat
representative of the
average patient
receiving prescription
benefits in Regie de
l’assurance maladie
du Quebec (1)
No description of
the derivation of
the cohort
(university-based
eye center) (0)
No description of the
derivation of the
cohort (0)
Selected group of
users (0)
Selection of the
nonexposed cohort
Drawn from the same
community as the
exposed cohort (1)
Drawn from the same
community as the
exposed cohort (1)
Drawn from the
same community
as the exposed
cohort (1)
Drawn from the same
community as the
exposed cohort (1)
Drawn from the
same community
as the exposed
cohort (1)
Ascertainment of
exposure
Medication history
collected from
medical records and
confirmed by phone
call (0)
Secure record (1) Secure record (1) Secure record (1) Secure record (1)
Demonstration that
outcome of interest
was not present at
start of study
Yes (1) Yes (1) No/NA (progression
as the only
outcome) (0)
Yes (1) Yes (1)
Comparability
Study controls for the
most important
factor*
Yes (1) Yes (1) Yes (1) Yes (1) Yes (1)
Study controls for any
additional factor†
DM, CCT, IOP,
refractive error (1)
No (0) DM, CCT, IOP (1) IOP, myopia (0) DM (0)
Outcome
Ascertainment of
outcome
Independent
assessment (1)
Record linkage (1) Independent
assessment (1)
Independent
assessment (1)
Record linkage (1)
Was follow-up long
enough for outcomes
to occur?
Yes (1) Yes (1) Yes (1) Yes (1) Yes (1)
Adequacy of follow-
up of cohort
Complete follow-
up—all subjects
accounted for (1)
Complete follow-
up—all subjects
accounted for (1)
Subject lost to
follow-up unlikely
to introduce bias:
0.4% lost to
follow-up (1)
Complete follow-
up—all subjects
accounted for (1)
Complete follow-
up—all subjects
accounted for (1)
Total score 7 8 7 7 7
CCT, central corneal thickness; DM, diabetes mellitus; IOP, intraocular pressure.
* If the study adjusted for age, one mark was scored.
† If the study adjusted for diabetes mellitus and relevant ocular parameters (central corneal thickness, intraocular pressure, or refractive error),
one mark was scored.
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Owen et al.10 from the meta-analysis of glaucoma incidence in
statin therapy not stratified by length of exposure also resulted
in no change to the statistical significance of the result (with
Owen et al.,10 OR 0.94, 95%CI 0.83, 1.06; without Owen, et
al.10 OR 0.86, 95%CI 0.66, 1.12). McGwin et al.9 was removed
from the meta-analyses in which it was included because it
scored <6 in NOS. Removal of the two McGwin et al.9 results
from the meta-analysis of glaucoma incidence in statin
exposure for 2 years resulted in no difference to the overall
estimate, which remained OR 0.96 (95%CI 0.94, 0.98). Removal
of McGwin et al.9 from the meta-analysis of glaucoma incidence
in statin exposure for >2 years resulted in a small change to the
overall estimate but no change to the statistical significance of
the result (with McGwin et al.,9 OR 0.88 95%CI 0.80, 0.97;
without McGwin et al.,9 OR 0.91, 95%CI 0.84, 0.98). Removal
of both McGwin et al.9 and Owen et al.10 from the meta-analysis
of glaucoma incidence in statin exposure for 2 years resulted
in no change to the statistical significance of the result (without
both, OR 0.96, 95%CI 0.93, 0.98). Removal of both McGwin et
al.9 and Owen et al.10 from the meta-analysis of glaucoma
incidence in statin therapy not stratified by length of exposure
resulted in no change to the statistical significance of the result
despite the change in the overall estimate and precision
(without both, OR 0.79, 95%CI 0.43, 1.45).
CONCLUSIONS
Analysis of the data with inclusion of ‘‘suspect to OAG’’ as
‘‘incidence’’ rather than ‘‘progression’’ supports our initial
conclusion that short-term statin therapy is associated with
reduced incidence of glaucoma. However, the reanalysis
following the suggestions by Ng et al.1 has revealed that long-
term statin therapy may be also associated with reduced
incidence of glaucoma. As in our initial review we recommend
caution when interpreting the results of the meta-analysis
because the results of the heavily weighted Stein et al.8 study
are susceptible to misclassification bias and its generalizability
is limited to the population with hyperlipidemia. We would
again like to thank Ng and colleagues for bringing to our
attention some of the limitations of the original analysis and
their valuable expertise.
Paul McCann
Ruth E. Hogg
Augusto Azuara-Blanco
Centre for Public Health, Queens University Belfast, Belfast,
United Kingdom.
E-mail: pmccann45@qub.ac.uk
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